Response to article - alternative interpretation of "there is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome".
作者信息
Tobacyk Julia, Brents Lisa K
机构信息
Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
出版信息
J Matern Fetal Neonatal Med. 2023 Dec;36(1):2183469. doi: 10.1080/14767058.2023.2183469.
Abstract
摘要
相似文献
1
Response to article - alternative interpretation of "there is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome".
J Matern Fetal Neonatal Med. 2023 Dec;36(1):2183469. doi: 10.1080/14767058.2023.2183469.
2
There is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome.
J Matern Fetal Neonatal Med. 2022 Dec;35(25):9227-9233. doi: 10.1080/14767058.2021.2022647. Epub 2022 Jan 2.
3
Placental aromatase expression decreased in severe neonatal opioid withdrawal syndrome.
J Matern Fetal Neonatal Med. 2021 Mar;34(5):670-676. doi: 10.1080/14767058.2019.1612870. Epub 2019 May 15.
4
A review of the literature: How does prenatal opioid exposure impact placental health and fetal brain development?
Dev Psychobiol. 2023 Apr;65(3):e22378. doi: 10.1002/dev.22378.
5
Placental DNA methylation profiles in opioid-exposed pregnancies and associations with the neonatal opioid withdrawal syndrome.
Genomics. 2021 May;113(3):1127-1135. doi: 10.1016/j.ygeno.2021.03.006. Epub 2021 Mar 9.
6
[Neonatal abstinence syndrome after maternal use of tramadol].
Ned Tijdschr Geneeskd. 2013;157(9):A5610.
7
The placenta as a target of opioid drugs†.
Biol Reprod. 2022 Apr 26;106(4):676-686. doi: 10.1093/biolre/ioac003.
8
A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome.
Pharmacol Ther. 2022 Jun;234:108045. doi: 10.1016/j.pharmthera.2021.108045. Epub 2021 Nov 20.
9
Transplacental methadone exposure and risk of Neonatal Opioid Withdrawal Syndrome.
Pharmacotherapy. 2024 Jan;44(1):22-27. doi: 10.1002/phar.2863. Epub 2023 Aug 23.
10
Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome.
Genomics. 2021 Nov;113(6):3610-3617. doi: 10.1016/j.ygeno.2021.08.001. Epub 2021 Aug 3.
本文引用的文献
1
There is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome.
J Matern Fetal Neonatal Med. 2022 Dec;35(25):9227-9233. doi: 10.1080/14767058.2021.2022647. Epub 2022 Jan 2.
2
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
N Engl J Med. 2010 Dec 9;363(24):2320-31. doi: 10.1056/NEJMoa1005359.
3
The effect of methadone and buprenorphine on human placental aromatase.
Biochem Pharmacol. 2006 Apr 14;71(8):1255-64. doi: 10.1016/j.bcp.2005.12.035. Epub 2006 Feb 7.
4
Methadone metabolism by human placenta.
Biochem Pharmacol. 2004 Aug 1;68(3):583-91. doi: 10.1016/j.bcp.2004.04.011.
5
Aromatase is the major enzyme metabolizing buprenorphine in human placenta.
J Pharmacol Exp Ther. 2003 Sep;306(3):1099-105. doi: 10.1124/jpet.103.053199. Epub 2003 Jun 13.
Zotero 插件